Alnylam Pharma (NASDAQ: ALNY) reported Q2 EPS of $1.84, $0.24 better than the analyst estimate of $1.60. Revenue for the quarter came in at $1.29 billion versus the consensus estimate of $1.32 billion.

GUIDANCE:

Alnylam Pharma sees FY2026 revenue of $4.2-4.5 billion, versus the consensus of $5.61 billion.

For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.